
    
      The study is planned to include approximately 45 healthy non-Japanese vasectomized male
      participants aged 18 to 55 years (inclusive) or male participants over 40 (and up to 55)
      years old not intending to father children will be enrolled. The study consists of 5 visits
      comprised of 3 treatment periods with 6 treatment sequences and will have a minimum washout
      period of 14 days between each treatment period.

      Visit 1: Screening period (28 days) - Assessments done on Day -1 of treatment period 1.

      Visits 2 to 4: 3 Treatment periods - Participants will be resident form day before IMP
      (single oral dose of AZD6094 (600 mg) tablet/AZD6094 matching placebo/moxifloxacin (400 mg)
      capsule) dosing (Day -1) until at least 48 hours post-dose and will be discharged on Day 3.

      Visit 5: Follow-up - Participants will have clinical visit 14 days after discharge from the
      treatment period 3.

      Participants will be randomized to 6 treatment sequences (ABC, ACB, BAC, BCA, CAB and CBA).
      In each sequence, participants will receive single oral dose of all 3 treatments (A - AZD6094
      600 mg (3X 200 mg tablet), B - Placebo tablet, C - Moxifloxacin 400 mg capsule) with a
      washout period (14 days) between each treatment period.

      The study duration will be approximately 84 days.
    
  